---
layout: default
title: Ropivacaine
parent: 僅模型預測 (L5)
nav_order: 557
evidence_level: L5
indication_count: 4
---

# Ropivacaine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **4** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ropivacaine: From Regional Anesthesia to Migraine Disorder

## One-Sentence Summary

Ropivacaine is an amide-type local anesthetic conventionally used for regional and surgical anesthesia via nerve blockade. The TxGNN model predicts it may have therapeutic value in **Migraine Disorder** when used as the injectate for sphenopalatine, stellate, or trigger-point nerve blocks, with **4 clinical trials** and **6 publications** currently supporting this direction.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not licensed in Saudi Arabia (drug not marketed, no license text on file); internationally used for regional/surgical anesthesia and acute pain management |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L2 |
| Saudi Arabia Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in structured form. Based on the available repurposing rationale, ropivacaine is an amide-class local anesthetic that blocks voltage-gated neuronal sodium channels, inhibiting nerve impulse conduction. It is not proposed here as a systemic drug for migraine — rather, it is the injectate used in interventional nerve-block procedures (sphenopalatine ganglion block, stellate ganglion block, thoracic sympathetic block, or paraspinal/trigger-point injection).

The mechanistic link to migraine is indirect: by blocking the trigeminovascular system and head/neck sympathetic-parasympathetic outflow pathways, these procedures may modulate migraine pathophysiology. This is an established interventional pain-medicine technique rather than a conventional systemic drug-repurposing scenario — ropivacaine functions as a procedural tool, and the "reuse" is really the reuse of the anesthetic block technique for a new target condition.

Because ropivacaine is not currently marketed in Saudi Arabia and no TFDA/Saudi package insert data is available (blocking data gap), the original approved indication and formal safety profile cannot be independently verified against this evidence pack — this is a material limitation on confidence, not just on the mechanistic story.

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT03666663](https://clinicaltrials.gov/study/NCT03666663) | Phase 4 | Completed | 10 | Randomized, double-blind, placebo-controlled trial of sphenopalatine ganglion block with nasal anesthetics (including ropivacaine) for migraine prevention; rigorous design but very small sample limits statistical power. |
| [NCT00680823](https://clinicaltrials.gov/study/NCT00680823) | N/A | Completed | 150 | Paraspinal intramuscular ropivacaine injection evaluated as a treatment for pediatric headache in an emergency department setting; completed with a reasonable sample size but non-RCT design. |
| [NCT05301387](https://clinicaltrials.gov/study/NCT05301387) | N/A | Completed | 38 | Sphenopalatine ganglion block vs. placebo, follow-up on long-term effects for postdural puncture headache — a related but distinct headache entity from classic migraine. |
| [NCT06470581](https://clinicaltrials.gov/study/NCT06470581) | N/A | Not yet recruiting | 78 | Thoracic sympathetic ganglion block trial; primary intervention is Botulinum Toxin Type A, with ropivacaine as a secondary/comparator component — low direct relevance. |

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [24284858](https://pubmed.ncbi.nlm.nih.gov/24284858/) | 2013 | Review | Pain Physician | Reviews transnasal topical sphenopalatine ganglion block techniques for headache and facial pain, including a novel procedural revision. |
| [35331152](https://pubmed.ncbi.nlm.nih.gov/35331152/) | 2022 | Cohort | BMC Anesthesiology | Observational study of real-time ultrasound-guided stellate ganglion block for migraine pain relief and quality-of-life improvement. |
| [17244105](https://pubmed.ncbi.nlm.nih.gov/17244105/) | 2007 | Cohort | Pain Medicine | Evaluates ropivacaine trigger-point inactivation as prophylactic treatment over a 12-week period in patients with severe migraine. |
| [30043973](https://pubmed.ncbi.nlm.nih.gov/30043973/) | 2019 | Cohort | Headache | Regional anesthetic sphenopalatine ganglion block assessed for self-reported pain relief in status migrainosus (attacks lasting >72 hours). |
| [19145569](https://pubmed.ncbi.nlm.nih.gov/19145569/) | 2009 | Case Report | Revista de Neurología | Case report of Horner's syndrome following epidural analgesia; only tangentially connected to migraine via TxGNN embedding similarity. |
| [17058040](https://pubmed.ncbi.nlm.nih.gov/17058040/) | 2006 | Case Report | The Journal of Headache and Pain | Case report describing migraine headache as a rare complication following cervicothoracic block. |

## Saudi Arabia Market Information

Ropivacaine currently has no market authorization on file in Saudi Arabia (0 licenses; market status: 未上市/Not marketed).

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Evidence is heterogeneous and mostly procedural (nerve-block technique) rather than systemic drug repurposing, the only placebo-controlled RCT (NCT03666663) is underpowered (n=10), and ropivacaine is not currently marketed in Saudi Arabia with no TFDA/package-insert safety data available — a blocking gap for any S1 safety review.

**To proceed, the following is needed:**
- TFDA/Saudi package insert data (warnings, contraindications) to clear the blocking safety gap (DG001)
- Structured mechanism-of-action confirmation from DrugBank (DG002)
- A larger, adequately powered RCT specifically evaluating ropivacaine-based nerve blocks for migraine (beyond the n=10 Phase 4 trial)
- Clarification of regulatory pathway, since the drug would need a Saudi Arabia marketing authorization before this indication could be pursued locally
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

